Biotech Co.* (Country;Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)
Affymetrix Inc. (AFFX) Partners HealthCare Extended research collaboration with a new contract array manufacturing supply agreement Affymetrix will create custom microarrays based on the recent discovery data from Partners researchers; the arrays will be used to produce molecular diagnostic tests (7/23)
Alfacell Corp. (ACEL) USP Pharma Spolka Z.O.O. (an affiliate of US Pharmacia) Eastern European distribution agreement for Onconase (ranpirnase), which is being developed for unresectable malignant mesothelioma USP gained exclusive rights to market and sell the drug in exchange for $100,000 up-front, $1.4M in a stock purchase agreement, potential milestone payments, reimbursements and double-digit royalties (7/26)
Ambrilia Biopharma Inc.(Canada; TSX:AMB) Shin Poong Pharmaceutical Co. (South Korea) Licensing and distribution agreement giving Shin Poong Korean rights to Ambrilia's sustained-release formulation of octreotide to treat acro-megaly; it is in Phase III trials Ambrilia is entitled to an up-front payment along with potential milestone payments; it will manufacture and supply the product to Shin Poong in exchange for a contractual price that includes royalties (7/17)
Biovitrum AB (Sweden; SSE:BVT) Wyeth Agreement to co-promote BeneFIX, a coagulation factor IX for hemophilia B, in Denmark, Finland, Iceland, Norway and Sweden Biovitrum will receive a commission on BeneFIX sales, including an additional incentive if certain sales targets are exceeded, for up to five years, with possible one-year extensions thereafter (8/8)
Depomed Inc. (DEPO) Watson Pharmaceuticals Inc. Co-promotion agreement for ProQuin XR, an extended-release formulation of ciprofloxacin hydrochloride to treat uncomplicated urinary tract infections Depomed granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialities in the U.S. and its possessions, including Puerto Rico; Depomed retains manufacturing and distribution rights (7/23)
Epitome Biosystems* EMD Chemicals Inc. (an affiliate of Merck KGaA) Licensing and development agreement focused on Epitome's EpiTag assays for the quantitative measurement of various targets, including membrane proteins Products will be manufactured, marketed and sold worldwide for research applications by EMD through its Novagen brand; terms were not disclosed (7/10)
InterMune Inc. (ITMN) Boehringer Ingelheim Austria

GmbH (unit of Boehringer Ingelheim; Germany)

 Supply agreement for Actimmune InterMune will pay BI Austria about $5.5M InterMune is not required to make any minimum annual purchase commitments, and BI Austria is not required to commit to reserving any minimum annual capacity for the manufacture of Actimmune (7/9)
Labopharm Inc. (Canada; DDSS) WhanIn Pharmaceutical Co. Ltd. (South Korea) Licensing and distribution agreement for South Korea for Labopharm's once-daily tramadol product WhanIn has exclusive rights to market and sell the product in South Korea; Labopharm will supply the product and is entitled to an up-front payment and sales revenues in the deal (7/11)
Laureate Pharma Inc.* Enobia Pharma Inc. A cGMP contract manufacturing agreement Laureate will produce Enobia's fusion protein for treatment of hypophosphatasia (7/31)
MediWound Ltd.* (Israel) Teva Pharmaceutical Industries Ltd. (Israel) Commercialization agreement for the Phase III burn debridement product, Debrase Teva gained commercialization rights to the drug in certain countries in exchange for purchasing $10M in shares from Medi-Wound's shareholders and $5M in newly issued shares (8/15)
Neoprobe Corp. (OTC BB:NEOP) Cardinal Health Term sheet for the marketing and distribution of LymphoSeek on an exclusive basis in the U.S. Lymphoseek is a radioactive lymphatic mapping targeting agent in development for use with handheld gamma detection devices during sentinel lymph node biopsy(7/12)
Protox Therapeutics

Inc. (Canada; CDNX:PRX)

 Dompe Farmaceutici SpA (Italy) Agreement for the clinical manufacture and commercial supply of PRX321, its lead candidate in development for the treatment of primary brain cancer Dompe will manufacture PRX321 at its facility in Italy for the upcoming pre-pivotal trial and has committed to supply commercial batches for five years following product registration; terms were not disclosed (7/17)
Santarus Inc. (SNTS) Victory Pharma Inc. Agreement to co-promote Victory's Naprelan (naproxen sodium) controlled-release tablets, a nonsteroidal anti-inflammatory drug indicated to treat arthritis and pain Santarus expects to begin promotional activities in the third quarter; it will be paid a co-promotion fee based on sales it generates (6/29)
Senetek plc (OTC BB:SNTKY) Triax Aesthetics LLC Marketing collaboration for Senetek's second-generation cytokinin with Triax, under which Senetek will provide $4.5M in the first-year sales and marketing payments Senetek has granted Triax an exclusive license in the ethical market channel in the U.S. and its territories, Canada and select Middle East countries; Senetek will receive all net product revenues in the first year, with a guaranteed minimum of $10.8M in 2008 (8/6)
Sinovac Biotech Ltd. (China; AMEX:SVA) GlaxoSmithKline (China) Investment Co. Ltd. Exclusive promotion service agreement to market and promote Anflu, a seasonal influenza vaccine GSK China's sales team will focus on the distribution of the adult dosage formulation while Sinovac will sell the pediatric formulation (8/1)
Sloning Biotechnology* (Germany) Research & Innovation Japan Inc. (Japan) Distribution partnership for RIJ to exclusively market and sell the Slonomics gene synthesis service and Slonomax product family of mutant libraries in Japan Financial terms were not disclosed (7/16)
Notes:
# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.